Myeloid-derived suppressive cells (MDSC) have been reported to promote metastasis, but the loss of cancer-induced B cells/B regulatory cells (tBreg) can block metastasis despite MDSC expansion in cancer. Here, using multiple murine tumor models and human MDSC, we show that MDSC populations that expand in cancer have only partially primed regulatory function and limited prometastatic activity unless they are fully educated by tBregs. Cancer-induced tBregs directly activate the regulatory function of both the monocyte and granulocyte subpopulations of MDSC, relying, in part, on TgfbR1/TgfbR2 signaling. MDSC fully educated in this manner exhibit an increased production of reactive oxygen species and NO and more efficiently suppress CD4 þ and CD8 
Introduction
The success of metastasis often depends on the ability of disseminating cancer cells to escape immune attack by using the help of regulatory immune cells, a heterogeneous group of specialized cells of granulocytic, myeloid, and lymphoid origins with seemingly redundant functions (1) . Among these, myeloid-derived suppressive cells (MDSC) are thought to be key inhibitors of antitumor effector cells and, as such, an independent prognostic factor of patient survival (2). As a group of immature cells poised to differentiate into granulocytes, dendritic cells, and macrophages, MDSC are subdivided into PMN-MDSC and Mo-MDSC cells (1, 3) on the basis of expression of Ly6G þ
Ly6C
Int/Low CD11b þ and
High Ly6G À CD11b þ in mice (4, 5) and
þ HLA-DR Low/À in humans (2, 6, 7), respectively. By producing granulocyte macrophage colony-stimulating factor (GM-CSF), VEGF, TGFb, IL-6, IL10, IL13, and PGE4, cancer not only drastically expands MDSC but also evokes their regulatory function (for reviews, see refs. 1, 8, 9) by inducing their production of reactive nitrogen and oxygen species (NO, ROS, H 2 O 2 , and peroxinitrite) through the IL4-Stat6-dependent expression of arginase 1 (Arg-1; ref. 10 ) and Stat1-and Stat3-induced expression of nitric oxide synthase (iNOS) and NADPH oxidase (NOX2; refs. 11, 12) . The expansion of MDSC is often used as a criterion of increased tumor burden and metastasis (1, 13) . However, using tumor models where MDSC were reported to be essential, we failed to detect the primary importance of MDSC in cancer metastasis. The loss of regulatory T cells (Treg) or B cells was sufficient to almost completely block the metastasis of the highly aggressive 4T1 cancer in BALB/c mice, a human model of triplenegative breast cancer (14) , and retard the growth of B16 melanoma in C57BL/6 mice (15) (16) (17) (18) . In the 4T1 model, cancer produces 5-lipoxygenase metabolites to convert B cells into a new subset of regulatory B cells, termed tumor-evoked regulatory B cells (tBreg; refs. 17, 19) , that induce FoxP3 þ Tregs to inactivate the antimetastatic natural killer (NK) and CD8 þ T cells (15, 17, 19) .
Here, using two different murine models and experimenting with human ex vivo-generated MDSC, we report that cancer only expands MDSC with partially activated regulatory function. As a result, the MDSC cannot support metastasis or promote tumor growth. We show that cancer uses B cells to evoke their full regulatory and thereby prometastatic function. Our modeling studies using specific TgfbR1 inhibitor and mice with TgfbR2 deficiency in myeloid cells suggest that cancerinduced B cells/tBregs evoke the full regulatory activity in MDSC via using, at least in part, the TgfbR1/TgfbR2 signaling axis. These results further underscore B cells/tBregs as key tumor messengers and initiators of the chain of suppressive events needed for metastasis.
Materials and Methods

Reagents, cells, and mice
TGFbRI (ALK5) inhibitor (SB431542) was purchased from Tocris Bioscience and catalase (1,000 U/mL) from Sigma Aldrich. L-NMMA and nor-NOHA (0.5 mmol/L) were from Cayman Chemical. Nitrate and NO were detected with the Griess Reagent Kit and DAF-FM diacetate, respectively, and ROS was detected with 1 mmol/L DHE (dihydroethidium) or DCFDA (2 0 ,7 0 -dichlorodihydrofluorescein diacetate) and was from Molecular Probes and used as described elsewhere (5) . a-TGFb neutralizing antibody (clone 1D11.16.8), a-mouse Gr1 (clone RB6-8C5), mouse IgG, and rat IgG2b were purchased from BioXcell.
The following flow cytometric antibodies and their isotype controls (from Biolegend and eBioscience, except otherwise specified) were used: CD11b APC or FITC (M1/70), Gr1 PE or FITC (RB6-8C5), Ly6G Alexa Fluor700 or PerCP Cy 5.5 (1A8), Ly6C Pacific blue or FITC (HK1.4), IL4Ra PE (I015F8), F4/80 PerCP Cy5.5 or APC (BM8), CD40 PE Cy7 (3/23), CD115 PE (AFS98), CD80 brilliant violet 421 (16-10A1), CD83 brilliant violet 650 (Michel-19), GrB FITC (GB11), and IFNg PE-Cy7 (XMG1.2). TgfbR antibodies were from R&D (TgfbR1, clone FAB5871A and TgfbR2, clone FAB532F).
For intracellular staining of phosphorylated Stat proteins, cells were fixed with 2% paraformaldehyde in PBS for 10 minutes at 37 C and resuspended in prechilled 90% methanol (in water). The cells were stained with anti-mouse CD11b Fitc, Ly6G PE-Cy7, Ly6C Pacific blue (Biolegend), and rabbit anti-mouse pStat1 or pStat3-Alexa Fluor 647 (Tyr705, Cell Signaling) at 1:200 dilution. For lineage-negative MDSC sorting, phycoerythrin (PE)-conjugated CD19 (clone 6D5), CD3 (clone 145-2C11), B220 (clone RA3-6B2), and CD49b (DX5) antibodies were used. Human sorting was performed using CD11b PE (clones M1/70) or CD14 Fitc (clone M5E2), CD19 PE (HIB19), CD3 PE, and CD56 PE antibodies (Biolegend and eBioscience).
4T1 adenocarcinoma cells and B16F10 melanoma cells were from ATCC. 4T1.2 cells, a subset of 4T1 cells, were a gift from Dr. Robin L. Anderson (Peter McCallum Cancer Center, Melbourne, Australia). Nonmetastatic 4T1.2-PE cells were described elsewhere (15) . Female (8-to 15-week-old) BALB/c, C57BL/6 mice, and J H T mice in C57BL/6 background (J H T; B6.129P2-IghJtm1Cgn/J) were from the Jackson Laboratory; mMT mice in BALB/c background were a gift from Professor Dr. Thomas Blankenstein (Max-Delbrück-Center for Molecular Medicine, Berlin, Germany); C57BL/6 mice with spontaneous ovarian cancer due to murine oviduct-specific glycoprotein promoter-driven expression of simian virus 40 large T-antigen (20) were housed at National Institute on Aging (Baltimore, MD) and TGFbRII 
In vitro manipulations
tBreg generation and T-cell suppression assays were performed as previously described (15 ) were subcutaneously injected into BALB/c mice or congenic mMT and TgfbR2 myeKO or J H T and C57BL/6 mice, respectively. At days 32 and 20 after 4T1 and B16-F10 cell injections, respectively, lung metastasis and tumor weight were evaluated as described elsewhere (15) . MDSC were isolated from mice after 25 to 30 and 18 to 20 days after 4T1 and B16 tumor challenge, respectively. Mice with spontaneous ovarian cancer were 12 to 15 weeks old. For adoptive transfer experiments, mice were intravenously injected with congenic 1.5 Â 10 6 to 10.0 Â 10 6 MDSC or tBregs at 1 to 3 days after tumor challenge. For Fig. 2B , the mice were tumor inoculated at day 0, and B-cell adoptive transfer was performed on day 18 (the late B-cell transfer was done to allow sufficient MDSC accumulation). MDSC were sorted 3 days after B-cell transfer to avoid the conversion of na€ ve B cells due to the tumor pressure.
a-mouse Gr1 depletion antibody was used at 100 mg/mouse intraperitoneal injections every fourth day. For the B-cell depletion experiments, mice were intraperitoneally injected with a-CD20 antibody (250 mg/mouse) on day 7 after tumor inoculation. Peripheral blood MDSC were assessed on day 28 after tumor inoculation.
Statistical analysis
The results are presented as the mean AE SEM. To assess significance between two groups, we used the Mann-Whitney test, whereas the Holm-Sidak method with a of 5.0% was used to correct for multiple comparison tests of tumor growth and titration curve analysis (Prism 6, GraphPad Software, Inc.).
Results
B-cell deficiency impairs the regulatory activity of MDSC
To understand the prometastatic role of MDSC, we subcutaneously implanted 4T1 cancer cells in the mammary gland of WT mice and B-cell-deficient mMT mice that do not generate tBregs (16, 17) . Tumor growth in the mammary gland was retarded (P < 0.005), and lung metastasis was blocked in mMT mice as compared with WT mice (P ¼ 0.028; Fig. 1A ). However, both mice comparably and strongly expanded MDSC (CD11b Next, we tested whether the loss of B cells/tBregs can impair the regulatory function of MDSC. To do this, we cocultured purified WT-and mMT-MDSC isolated from individual mice challenged with 4T1 cancer at the same time (n ¼ 9, from here on, unless specified, the MDSC were only isolated from tumor-bearing mice) with na€ ve mouse T cells stimulated with anti-CD3/CD28 Abs for 5 days. At the cell-to-cell comparisons, while WT-MDSC strongly inhibited proliferation (Fig. 1D ) and production of granzyme B (GrB; Fig. 1E ) and IFNg (Fig. 1F) in CD8 þ T cells, mMT-MDSC were significantly less efficient (P < 0.001; Fig. 1D-F) . To further confirm this result, we also tested suppressive activity of individual subsets of MDSC by coculturing sort-purified PMN-MDSC and Mo-MDSC with T cells stimulated with anti-CD3/CD28 Abs. Despite overall stronger activity of PMN-MDSC over Mo-MDSC, both mMT-MDSC subsets inhibited less efficiently CD4 þ and CD8 þ T cells as compared with their respective WT subsets (P < 0.001; Fig. 1G and Supplementary Fig. S1C ). Because the suppression involves NO and ROS, their production could be impaired in mMT-MDSC. In support, specific inhibitors NOHA, L-NMMA, and particularly catalase (scavenges H 2 O 2 , dismutation product of ROS), almost completely abolished the ability of MDSC to suppress T-cell proliferation ( Supplementary Fig. S1D and S1E). The relative expression levels of NOX2 and Arg genes were significantly reduced in mMT-MDSC as compared with WT-MDSC (Supplementary Fig. S2A and S2B). In concordance, nitrate production (the NO readout) was only detected in WT Mo-MDSC, but not PMN-MDSC or mMT-MDSC, cultured with T cells (P ¼ 0.028 as compared with mMT-MDSC; Fig. 1H ). Fig. 1I ), respectively. Moreover, ROS production in WT-MDSC of tumor-bearing WT mice was further increased (P < 0.03; Supplementary Fig. 2C ) if the mice were treated with a-CD20 Ab that enriches for tBregs via depleting B cells (17) . Thus, given that mMT mice do not generate tBregs (17) , these results suggest that the regulatory function of MDSC requires tBregs.
tBregs activate the regulatory function of cancer-primed MDSC To test this possibility, we transferred B cells from na€ ve (B-cont) or tumor-bearing WT mice (B-tumor, which contain tBregs; ref. 17) into mMT mice (n ¼ 5 per group; Fig. 2A ). After 3 days, peripheral blood MDSC were isolated and tested for suppression of T-cell proliferation. mMT-MDSC from B-conttransferred mice suppressed proliferation of CD8 þ T cells slightly stronger than the ones from mock-treated mice (Fig. 2B) , presumably due to some in vivo conversion of B-cont cells into tBregs (16, 17) . However, mMT-MDSC from mice transferred with Btumor inhibited T-cell proliferation significantly stronger (P < 0.001; Fig. 2B ) and produced higher levels of ROS (P ¼ 0.029 as compared with B-cont-transferred mouse Mo-MDSC and PMN-MDSC, respectively; Fig. 2C ). Thus, these experiments reproduced at least 3 independent times indicate that the full regulatory function of MDSC in mice requires tBregs. In concordance, the transfer of ex vivo-generated tBregs also significantly increased the suppressive activity of MDSC in mMT mice (P < 0.008; Fig. 2D ), besides restoring lung metastasis ( Fig. 1C and also refs. [16] [17] [18] .
tBregs educate MDSC promoting cancer escape and metastasis To understand how tBregs activate MDSC, we performed in vitro experiments by coculturing freshly purified mMT-MDSC with na€ ve mouse B cells (B-cont), or with tBregs, or B cells from tumor-bearing mice (B-tumor). After 5-hour incubation, the MDSC were depleted of B cells and mixed with T cells stimulated with anti-CD3/CD28 Ab. Unlike B-cont, the pretreatment of mMT-MDSC with B-tumor ( Fig. 3A and B) or tBregs (Fig. 3C and D and Supplementary Fig. S3A ) strongly (P ¼ 0.029) and in a dosedependent manner inhibited T-cell proliferation and ROS. The treatment also blocked production of key factors required for successful antitumor activity of CD8 þ T cells (17, 23) , such as GrB and IFNg ( Supplementary Fig. S3A-S3C ). The B-tumor and tBregstimulated mMT-MDSC also expressed higher levels of NOX2, iNOS, and Arg1 genes ( Supplementary Fig. S4A-S4G ) and produced more ROS (P < 0.03; Fig. 3B and D) than B-conttreated MDSC. They also upregulated expression of IL10 and TGFb ( Supplementary Fig. S4E and S4F ) and other factors associated with regulatory MDSC, such as IL4Ra, CD80, CD83, CD40, and phosphorylated Stat1 and Stat3 (Fig. 3E and Supplementary Fig. S4H ). The mMT-MDSC also upregulated surface expression of TgfbR1 (P < 0.03) and TgfbR2 (P < 0.002) upon stimulation with tBregs ( Supplementary Fig. S4I ). When we transferred these mMT-MDSC (pretreated with B-tumor/tBregs) into mMT mice, the mice succumbed to significant lung metastasis (P < 0.03; Fig. 3F ). In contrast, B-cont-pretreated mMT-MDSC failed to restore metastasis in mMT mice. Thus, these results, which were independently confirmed in multiple experiments, indicate that tBregs directly evoke the regulatory and thereby prometastatic function of MDSC.
Murine and human cancer B cells can also educate MDSC Similar "education" of MDSC appears to also occur in other mouse backgrounds and tumor models, as the growth of a highly aggressive B16 melanoma is also retarded in B-cell-deficient J H T mice compared with congenic C57BL/6 mice (17) (18) (19) 24) . To test this possibility, we adoptively transferred J H T mice bearing B16 melanoma with MDSC purified from WT C57BL/6 mice with orthotopic B16 melanoma or with spontaneous ovarian cancer (WT B16-MDSC and OC-MDSC, respectively; ref. 20). Unlike MDSC from J H T mice with B16 melanoma (J H T B16-MDSC), the transfer of WT B16-MDSC and OC-MDSC reversed the retarded tumor growth in J H T mice yielding significantly larger tumors (P < 0.05; Fig. 4A ). Moreover, WT B16-MDSC and OC-MDSC also produced higher levels of ROS (P < 0.03; Fig. 4B ) and nitric oxide (P < 0.03; Fig. 4C ) and strongly inhibited CD4 þ and CD8 þ T-cell proliferation (P ¼ 0.03; Fig. 4D ). To see whether similar education can also occur in human MDSC, healthy donor PBMC depleted of T and NK cells (but with or without CD19 þ B-cell depletion) were treated with conditioned medium (CM) from MDA-MB-231 breast cancer cell line, Fig. 4F and Supplementary Fig. S5C ). Taken together, these results indicate that both murine and human cancer-exposed B cells/Bregs can evoke the regulatory function of MDSC.
tBregs educate MDSC by triggering TGFb signaling Given that murine and human tBregs convert metastasis-promoting FoxP3 þ Tregs by overexpressing TGFb (16, 18) and the fact that the TgfbR2 deficiency in myeloid cells abrogates 4T1 cancer metastasis (21), we tested whether TGFb can be involved in the education of MDSC. As murine tBregs and human tBreg-like cells generated after treatment with CM of MDA-MB-231 cells (16, 18) , the B16/OC-associated B cells expressed elevated levels of TGFb compared with na€ ve B cells (Supplementary Fig. S6A ). Thus, we tested the role of TGFb in this process by coculturing tBregs with mMT-MDSC in the presence of TGFb blocking or control Ab. Then, MDSC (after removal of B cells) were tested in T-cell suppression assay. The TGFb neutralization during the education of MDSC significantly abrogated the ability of MDSC to inhibit T-cell proliferation (P < 0.03; Fig. 5A and Supplementary Fig. S3 ). To confirm this finding, we also cocultured mMT-MDSC with tBregs in the presence of a specific TgfbR1 inhibitor SB431542. The . After B-cell depletion, the MDSC were used in T-cell suppression assays as in Fig. 1G (A, C) or adoptively transferred in tumor-bearing mMT mice to assess lung metastasis (F). For the education experiment, we used ex vivo-generated tBregs or B-tumor cells sort-purified from at least three WT mice with tumor. B cells were mixed with MDSC isolated from three mMT tumor-bearing mice. Each experiment was reproduced at least three times. Ã , P < 0.05; ÃÃ , P < 0.01; ÃÃÃ , P < 0.001. NS, not significant.
inhibitor indeed abrogated expression of iNOS, NOX2, and Arg ( Supplementary Fig. S4A-S4C ) and ROS production in MDSC (P < 0.03; Fig. 5B and Supplementary Fig. S6B ). Importantly, upon transfer of the mMT-MDSC educated in the presence of SB431542 (after depletion of B cells and several washes with PBS to remove traces of the inhibitor) into mMT mice with 4T1 cancer, they yielded significantly fewer metastatic foci in the lungs than control tBreg-educated mMT-MDSC (P < 0.03; Fig. 5C ). Note the fact that the residual metastasis after the transfer of TgfbR1-inactivated mMT-MDSC could be due to the fact that SB431542 only partially blocked ROS production in PMN-MDSC ( Fig. 5B and Supplementary Fig. S6B ). To further verify the importance of TGFb signaling, we also used MDSC from mice with TgfbR2 deficiency in myeloid cells (TgfbR2 KO). Although ROS/NO was reduced in TgfbR2 KO MDSC of mice with B16 melanoma (Fig. 4B and C) and 4T1 cancer ( Supplementary Fig. S6C ) as in mMT-MDSC, tBregs failed to upregulate its expression as in mMT-MDSC (Supplementary Fig. S6C ). Importantly, unlike mMT-MDSC, tBregs failed to increase the suppressive activity of TgfbR2 KO MDSC on CD4 þ and CD8 þ T cells (P < 0.03; Fig. 5D ). Upon their transfer into mMT mice, they also supported the lung metastasis of 4T1 cancer cells less efficiently (P < 0.03; Fig. 5E ). In summary, these results confirmed in multiple independent experiments suggest that tBregs educate MDSC, at least in part, by targeting the TgfbR1/2 axis. A similar mechanism appears to be used by human myeloid cells, as SB431542 also impaired their education with ex vivo-generated tBregs ( Fig. 4E and Supplementary  Fig. S5B ) and tBreg-like cells of B-CLL ( Fig. 4F and Supplementary Fig. S5C ), significantly (P < 0.03) reducing their ability to suppress T-cell proliferation.
Discussion
Here, we attempted to mechanistically reconcile the issue raised in our previous studies questioning the importance of MDSC in metastasis. We repeatedly noticed that metastasis was blocked if B cells/tBregs were lost (16) (17) (18) (19) despite the fact that cancer drastically expanded MDSC, the key facilitators of cancer escape and metastasis (1, 13 (4) and to upregulate ROS and NO production in MDSC. As a result, MDSC become fully suppressive for T cells and thereby prometastatic (5). Ã , P < 0.05; ÃÃ , P < 0.01; ÃÃÃ , P < 0.001. NS, not significant.
but not control, Ab was sufficient to inhibit the MDSC education in vitro. Second, when we blocked TgfbR1 signaling with a specific inhibitor SB431542 during the education of mMT-MDSC with tBregs, we failed to detect the upregulation of ROS production and suppression of T cells. As a result, these MDSC supported metastasis less efficiently in mMT mice upon their adoptive transfer. Similarly, the TgfbR1 inhibitor also blocked the education of human MDSC by tBregs induced by CM of MDA-MB-231 cells and tBreg-like cells of patients with B-CLL. We also confirmed these results using MDSC from tumor-bearing mice with myeloid cells deficient in TgfbR2, which is required for the signaling of TgfbR1 (27) . Unlike mMT-MDSC, tBregs failed to educate MDSC with TgfbR2 KO, as shown by the loss of upregulation of ROS production, T-cell inhibition, and ability to support metastasis upon transfer into mMT mice. Thus, these results unequivocally indicate that cancer-induced B cells and tBregs render the full regulatory function of MDSC by, at least, targeting their TgfbR1/ TgfbR2 signaling axis. In support, others recently reported that 4T1 cancer also fails to metastasize in BALB/c mice deficient in TgfbR2 in myeloid cells (21) , suggesting that this is due to the inability of their MDSC to get education from tBregs.
Our ex vivo studies with human MDSC and 3 murine tumor models tested so far, such as mice with 4T1 cancer, B16 melanoma, and spontaneous ovarian cancer, suggest that the MDSC education is a common feature of cancer-activated B cells/Bregs. As in 4T1 cancer model (where tBregs induce MDSC), the loss of mature B cells also impaired the regulatory and tumor-augmenting functions of MDSC in mice with B16 melanoma that does not generate tBregs. Moreover, unlike na€ ve mouse B cells that cannot educate MDSC nor promote tumor growth (17) (18) (19) , B cells from mice with B16 melanoma and spontaneous ovarian cancer not only induced regulatory activity of MDSC and reversed the retarded tumor growth in B-cell deficient mice but also upregulated TGFb as in tBregs (18) . Similarly, B cells were required for the ex vivo generation of suppressive myeloid cells from the peripheral blood of healthy human donors, as their removal or the blockage of TgfbR1 signaling abrogated the generation of suppressive myeloid cells. Finally, tBreg-like cells of patients with B-CLL, but not B cells from patients without tBregs or from healthy donors, also induced the generation of suppressive myeloid cells using TgfbR1 signaling.
In summary, our data indicate that the generation of regulatory MDSC is a 2-step process (Fig. 5F ). While drastically expanding MDSC, probably using GM-CSF, IL1b, VEGF, TGFb, and other factors (1, 13, 28) , cancer also activates their inducers, such as tBregs in mice with 4T1 cancer and ovarian cancer (16, 17) or/and yet to be identified Bregs in mice with B16 melanoma. Na€ ve B cells do not educate MDSC. Although the nature and induction of cancer-induced B cells in mice with B16 melanoma is a focus of a separate study, we recently reported that 4T1 cancer directly induces the generation of tBregs from B2 cells via production of 5-lipoxygenase metabolites (19) . The reasons behind the 2-step activation process for MDSC remain unclear. This can be a way to limit the use of MDSC only at the sites of inflammation and metastasis, such as the tumors and lungs, via triggering the feedback loop induced by TGFb and ROS/NO, as shown for other cells (29) (30) (31) where the activation of TGFb and production of ROS/H 2 O 2 /NO are mutually regulated. In concordance, mMT-MDSC became fully regulatory and prometastatic within a brief (<5 hours) encounter with tBregs. The education not only increased a number of surface molecules linked with regulatory MDSC (e.g., IL4Ra, TGFb, and IL10) but also upregulated surface expression of TgfbRs presumably as a part of the feedback loop. Thus, the education may also bring additional factors that further augment the differentiation and regulatory function of MDSC, the focus of a different study. On the other hand, it is tempting to speculate that the early stage of cancer requires tBregs to support metastasis of 4T1 cancer via inducing metastasis-protecting FoxP3 þ Tregs (17), as we detect tBregs at least 1 week before the massive expansion of MDSC. As such, the loss of Tregs mostly blocks 4T1 cancer metastasis without affecting primary tumor growth (15, 17) . At the later stage of cancer, tBregs appear to be needed to counteract the induction of antitumor myeloid cells (8) by switching and enhancing their regulatory function. Overall, the data presented here further underscore the importance of B cells in cancer (24, (32) (33) (34) (35) (36) by adding for the first time the education of MDSC to a growing list of protumorigenic functions, such as the inhibition of cytotoxic CD8 þ T and NK cells (37) , Treg conversion (38) , and M1-to-M2 macrophage polarization (39, 40) . As such, B cells have to be targeted to enhance antitumor immune responses.
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